Multidose Priming and Delayed Boosting ImprovePlasmodium falciparumSporozoite Vaccine Efficacy Against HeterologousP. falciparumControlled Human Malaria Infection
Abstract
A live-attenuated Plasmodium falciparum sporozoite (SPZ) vaccine (PfSPZ Vaccine) has shown up to 100% protection against controlled human malaria infection (CHMI) using homologous parasites (same P. falciparum strain as in the vaccine). Using a more stringent CHMI, with heterologous parasites (different P. falciparum strain), we assessed the impact of higher PfSPZ doses, a novel multi-dose prime regimen, and a delayed vaccine boost upon vaccine efficacy (VE).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 12, 2020
- Source ID
- 10.1093/cid/ciaa1294
Entities
People
- Alexandra Singer
- Amelia Ozemoya
- Anatalio Reyes
- Andrea A Berry
- Anita Manoj
- Anusha Gunasekera
- Arnel Belmonte
- B. Kim Lee Sim
- Eileen Villasante
- Eric R. James
- Glenna Banania
- Harini Ganeshan
- Ivelese Guzman
- Judith E. Epstein
- Kirsten E. Lyke
- Lindsey S Garver Baldwin
- Maria Belmonte
- Martha Sedegah
- Matthew B. Laurens
- Mimi Wong
- Peter F. Billingsley
- Sharina Reyes
- Stephen L. Hoffman
- Sumana Chakravarty
- Thomas L. Richie
- Tony Jun Huang
- Tooba Murshedkar
- W Preston Church
- Warfighter Ii Study Team
Organizations
- Centre Pour le Développement des Vaccins-Mali
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Naval Medical Research Center
- United States Department of Defense